12 results
·
6ms
·
Sources: EU EUDAMED, US FDA
Surface Applicator Set with Leipzig-style Cone. Brachytherapy applicator set.
FDA Enforcement
Class II
·Terminated·Varian Medical Systems Inc·July 1, 2015
The VariSource iX series afterloader systems are computer controlled remote electro/mechanical systems used for medical purposes, for placing a cable incorporating an irradiated iridium seed internally or close by a malignant tumor or tumor bed in a practice known as brachytherapy.
FDA Enforcement
Class II
·Terminated·Varian Medical Systems Inc·July 8, 2015
Cobas b 221 (versions 5 and 6) Blood Gas and Electrolytes Analyzer
FDA Enforcement
Class II
·Terminated·Roche Diagnostics Operations, Inc.·February 11, 2015
FGFR RGQ RT-PCR Kit (RUO, not IVD) REF 8747010
FDA Enforcement
Class II
·Ongoing·Qiagen Sciences LLC·September 7, 2022
therascreen FGFR RGQ RT-PCR kit (US IVD) REF 874721
FDA Enforcement
Class II
·Ongoing·Qiagen Sciences LLC·September 7, 2022
therascreen EGFR RGQ PCR Kit (24), Reference Number REF 870121
FDA Enforcement
Class II
·Terminated·Qiagen Sciences LLC·June 17, 2020
Kelyniam Custom Skull Implant (CSI), Model no. PEEK-IM1004
FDA Enforcement
Class II
·Terminated·Kelyniam Global, Inc.·May 23, 2018
therascreen KRAS RGQ PCR Kit (24) Model Number(s): REF 870021 (US IVD)
FDA Enforcement
Class II
·Ongoing·Qiagen Sciences LLC·April 27, 2022
therascreen FGFR RGQ RT-PCR Kit (CE IVD, not sold in the US) REF 874711
FDA Enforcement
Class II
·Ongoing·Qiagen Sciences LLC·September 7, 2022
therascreen KRAS RGQ PCR Kit (24) REF 874052 (Japan IVD, not released in the USA)
FDA Enforcement
Class II
·Ongoing·Qiagen Sciences LLC·April 27, 2022
therascreen PIK3CA RGQ PCR Kit (23) US IVD product- aid clinicians in identifying breast cancer patients who may be eligible for treatment with PIQRAY (alpelisib) based on a PIK3CA Mutation Detected result. REF 873121
FDA Enforcement
Class II
·Terminated·Qiagen Sciences LLC·February 3, 2021
therascreen ¿KRAS RGQ PCR Kit (24)-IVD qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of seven somatic mutations in the human KRAS oncogene REF 870021 (US IVD)
FDA Enforcement
Class II
·Ongoing·Qiagen GmbH·October 11, 2023